110958-19-5
Chemical Structure
Fasoracetam
Synonym(s): NS 105
- CAS No.: 110958-19-5
- Formula:C10H16N2O2
- Molecular Weight:196.25
IUPAC Name: (R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one
InChIKey: GOWRRBABHQUJMX-MRVPVSSYSA-N
SMILES: O=C([C@@H]1NC(CC1)=O)N2CCCCC2
Biological Activity: Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia[1][2][3][4][5].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fasoracetam | 99.41% | Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fasoracetam (Standard) | ≥98% | Fasoracetam (NS 105) Standard is the analytical standard of Fasoracetam (HY-107481). This product is intended for research and analytical applications. Fasoracetam (NS105) is an orally active metabotropic glutamate receptor (mGluR) activator. Fasoracetam bidirectionally regulates adenylyl cyclase activity and cAMP levels by activating group I-III mGluRs, upregulating GABAB receptors, and enhancing cholinergic neurotransmission. Fasoracetam can be used in research on attention deficit hyperactivity disorder (ADHD), depression, dementia, Alzheimer's disease, and forebrain ischemia. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Elia J, et al. Fasoracetam in adolescents with ADHD and glutamatergic gene network variants disrupting mGluR neurotransmitter signaling. Nature communications. 2018 Jan 16;9(1):4. [Content Brief]
- [2]. Hirouchi M, et al. Role of metabotropic glutamate receptor subclasses in modulation of adenylyl cyclase activity by a nootropic NS-105. European journal of pharmacology. 2000 Jan 03;387(1):9-17. [Content Brief]
- [3]. Oka M, et al. Involvement of metabotropic glutamate receptors in Gi- and Gs-dependent modulation of adenylate cyclase activity induced by a novel cognition enhancer NS-105 in rat brain. Brain research. 1997 Apr 18;754(1-2):121-30.
- [4]. Ogasawara T, et al. Involvement of cholinergic and GABAergic systems in the reversal of memory disruption by NS-105, a cognition enhancer. Pharmacology, biochemistry, and behavior. 1999 Sep;64(1):41-52. [Content Brief]
- [5]. Shorvon S. Pyrrolidone derivatives. The Lancet. 2001 Dec 1;358(9296):1885-92. [Content Brief]
